PortfoliosLab logoPortfoliosLab logo

Documentation

Upgrade your plan
ARKG vs. IDNA
Performance
Return for Risk
Drawdowns
Volatility
Dividends

ARKG vs. IDNA

Last updated Jun 23, 2026

ARKG (ARK Genomic Revolution Multi-Sector ETF) and IDNA (iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund) are both Health & Biotech Equities funds. ARKG is actively managed, while IDNA is passively managed. Over the past 5 years, ARKG returned -16.18%/yr vs -8.07%/yr for IDNA. Their correlation of 0.85 suggests significant overlap in exposure. ARKG charges 0.75%/yr vs 0.47%/yr for IDNA.

Performance

ARKG vs. IDNA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in ARK Genomic Revolution Multi-Sector ETF (ARKG) and iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, ARKG achieves a 25.65% return, which is significantly higher than IDNA's 17.72% return.

ARKG

1D
-1.25%
1M
18.68%
YTD
25.65%
6M
18.88%
1Y
52.94%
3Y*
3.54%
5Y*
-16.18%
10Y*
8.79%

IDNA

1D
0.46%
1M
4.69%
YTD
17.72%
6M
14.99%
1Y
51.77%
3Y*
10.60%
5Y*
-8.07%
10Y*
—
*Multi-year figures are annualized to reflect compound growth (CAGR)

ARKG vs. IDNA - Yearly Performance Comparison

2026 (YTD)2025202420232022202120202019
ARKG
ARK Genomic Revolution Multi-Sector ETF		25.65%23.04%-28.24%16.22%-53.90%-33.92%180.40%12.62%
IDNA
iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund		17.72%17.26%-0.72%-7.63%-42.28%-3.98%54.30%22.10%

Correlation

The correlation between ARKG and IDNA is 0.76, which is moderate. They share some common price drivers but move independently often enough to provide real diversification benefit when combined.

Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.76

Correlation (3Y)
Calculated over the trailing 3-year period

0.79

Correlation (5Y)
Calculated over the trailing 5-year period

0.84

Correlation (All Time)
Calculated using the full available price history since Jun 13, 2019

0.85

The correlation between ARKG and IDNA has been stable across timeframes, ranging from 0.76 to 0.85 - a consistent structural relationship.

ARKG vs. IDNA - Sectors Allocation Comparison

Sectors
ARKG
IDNA

Healthcare

99.3%
99.3%

Financial Services

0.5%

-

Basic Materials

-

-

Communication Services

-

-

Consumer Cyclical

-

-

Consumer Defensive

-

-

Energy

-

-

Industrials

-

0.3%

Real Estate

-

-

Technology

-

-

Utilities

-

-

Healthcare

ARKG
99.3%
IDNA
99.3%

Financial Services

ARKG
0.5%
IDNA

-

Basic Materials

ARKG

-

IDNA

-

Communication Services

ARKG

-

IDNA

-

Consumer Cyclical

ARKG

-

IDNA

-

Consumer Defensive

ARKG

-

IDNA

-

Energy

ARKG

-

IDNA

-

Industrials

ARKG

-

IDNA
0.3%

Real Estate

ARKG

-

IDNA

-

Technology

ARKG

-

IDNA

-

Utilities

ARKG

-

IDNA

-

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

ARK Genomic Revolution Multi-Sector ETF

iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund

Often compared with ARKG:
ARKG vs. ARKKARKG vs. XBIARKG vs. IBBARKG vs. GNOMARKG vs. ARKQARKG vs. ARKWARKG vs. SPY
Often compared with IDNA:
IDNA vs. GNOMIDNA vs. PBEIDNA vs. IBBIDNA vs. BBHIDNA vs. HELXIDNA vs. WDNAIDNA vs. XGEN.DE

Return for Risk

ARKG vs. IDNA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.
ARKG
ARKG Risk / Return Rank: 3636
Overall Rank
ARKG Sharpe Ratio Rank: 3636
Sharpe Ratio Rank
ARKG Sortino Ratio Rank: 3838
Sortino Ratio Rank
ARKG Omega Ratio Rank: 3333
Omega Ratio Rank
ARKG Calmar Ratio Rank: 4040
Calmar Ratio Rank
ARKG Martin Ratio Rank: 3333
Martin Ratio Rank
IDNA
IDNA Risk / Return Rank: 7070
Overall Rank
IDNA Sharpe Ratio Rank: 6666
Sharpe Ratio Rank
IDNA Sortino Ratio Rank: 6666
Sortino Ratio Rank
IDNA Omega Ratio Rank: 5555
Omega Ratio Rank
IDNA Calmar Ratio Rank: 8888
Calmar Ratio Rank
IDNA Martin Ratio Rank: 7474
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ARKG vs. IDNA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for ARK Genomic Revolution Multi-Sector ETF (ARKG) and iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

ARKGIDNADifference
Sharpe ratioReturn per unit of total volatility
1.25
2.09

-0.84

Sortino ratioReturn per unit of downside risk
1.92
2.92

-1.00

Omega ratioGain probability vs. loss probability

1.22

1.33

-0.11

Calmar ratioReturn relative to maximum drawdown

1.93

4.88

-2.94

Martin ratioReturn relative to average drawdown

4.60

13.60

-9.00

ARKG vs. IDNA - Sharpe Ratio Comparison

The current ARKG Sharpe Ratio is 1.25, which is lower than the IDNA Sharpe Ratio of 2.09. The chart below compares the historical Sharpe Ratios of ARKG and IDNA, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Loading charts...

Drawdowns

ARKG vs. IDNA - Drawdown Comparison

The maximum ARKG drawdown since its inception was -83.59%, which is greater than IDNA's maximum drawdown of -68.26%. Use the drawdown chart below to compare losses from any high point for ARKG and IDNA.

Loading charts...

Drawdown Indicators

ARKGIDNADifference

Max Drawdown

Largest peak-to-trough decline

-83.59%

-68.26%

-15.33%

Max Drawdown (1Y)

Largest decline over 1 year

-27.51%

-10.66%

-16.85%

Max Drawdown (3Y)

Largest decline over 3 years

-51.96%

-29.46%

-22.50%

Max Drawdown (5Y)

Largest decline over 5 years

-80.18%

-68.26%

-11.92%

Max Drawdown (10Y)

Largest decline over 10 years

-83.59%

—

—

Current Drawdown

Current decline from peak

-67.43%

-41.96%

-25.47%

Average Drawdown

Average peak-to-trough decline

-36.00%

-36.28%

+0.28%

Ulcer Index

Depth and duration of drawdowns from previous peaks

11.53%

3.82%

+7.71%

Volatility

ARKG vs. IDNA - Volatility Comparison

ARK Genomic Revolution Multi-Sector ETF (ARKG) has a higher volatility of 15.26% compared to iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA) at 7.25%. This indicates that ARKG's price experiences larger fluctuations and is considered to be riskier than IDNA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Loading charts...

Volatility by Period

ARKGIDNADifference

Volatility (1M)

Calculated over the trailing 1-month period

15.26%

7.25%

+8.01%

Volatility (6M)

Calculated over the trailing 6-month period

30.89%

18.40%

+12.49%

Volatility (1Y)

Calculated over the trailing 1-year period

42.61%

24.97%

+17.64%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

45.93%

28.46%

+17.47%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

41.30%

29.52%

+11.78%

ARKG vs. IDNA - Expense Ratio Comparison

ARKG has a 0.75% expense ratio, which is higher than IDNA's 0.47% expense ratio.

Dividends

ARKG vs. IDNA - Dividend Comparison

ARKG has not paid dividends to shareholders, while IDNA's dividend yield for the trailing twelve months is around 0.91%.

PositionTTM202520242023202220212020201920182017
ARKG
ARK Genomic Revolution Multi-Sector ETF		0.00%0.00%0.00%0.00%0.00%0.62%0.85%3.14%0.82%1.34%
IDNA
iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund		0.91%1.18%0.98%1.04%0.54%0.70%0.26%0.80%0.00%0.00%

Frequently Asked Questions

ARKG and IDNA have a correlation of 0.76, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

ARKG has higher volatility (15.26%) compared to IDNA (7.25%). In terms of maximum drawdown, ARKG dropped -83.59% vs IDNA's -68.26%.

On 5-year performance, IDNA leads with -8.07% vs -16.18% for ARKG. On fees, IDNA is cheaper at 0.47% per year. On volatility, IDNA has been the lower-risk option at 7.25%. The better choice depends on whether you care most about return, fees, risk, or income.

Over the 5-year period, IDNA has performed better with a -8.07% return vs -16.18%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.

IDNA is cheaper with a 0.47% expense ratio, compared with 0.75% for ARKG.

IDNA has the higher dividend yield at 0.91%, compared with 0.00% for ARKG.

They also come from different issuers: ARK and iShares. Their fees differ too: 0.75% for ARKG and 0.47% for IDNA.

IDNA currently has the higher Sharpe Ratio (2.09 vs 1.25), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for ARKG and IDNA

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer